India Globalization Capital’s IGC-AD1 for Alzheimer’s disease (AD) symptoms saw its Phase Transition Success Rate (PTSR) surge 15 points to 73% after completing its Phase I trial. The PTSR update occurred on 25 June after IGC announced on 23 June it completed the final cohort of its 12-patient Phase I. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

The multiple ascending dose Phase I trial (NCT04749563) has a primary endpoint assessing safety, and changes in the Neuropsychiatric Inventory (NPI) scale as a secondary efficacy endpoint. IGC-AD1, which uses the psychoactive component of cannabis THC, is designed to help improve the lifestyle of patients with AD.

Phase I completion also generated a modest 2-point bump in the drug’s Likelihood of Approval (LoA), which rose to 9%. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. It is calculated by compounding the PTSR at each stage the drug is yet to progress through. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

IGC has a market cap of $67.6m.

William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.